What is SKYRIZI (risankizumab-rzaa)?
Last Reviewed: May 2019.
- AbbVie Expands Immunology Portfolio in the U.S. with FDA Approval of SKYRIZI™ (risankizumab-rzaa) for Moderate to Severe Plaque Psoriasis. April 23, 2019. https://news.abbvie.com/news/press-releases/abbvie-expands-immunology-portfolio-in-us-with-fda-approval-skyrizi-risankizumab-rzaa-for-moderate-to-severe-plaque-psoriasis.htm, Accessed April 25, 2019.
- Phototherapy. National Psoriasis Foundation. Available at: https://www.psoriasis.org/about-psoriasis/treatments/phototherapy Accessed April 25, 2019.
- SKYRIZI™ (risankizumab-rzaa). AbbVie Inc. Available at: https://www.skyrizihcp.com Accessed May 8, 2019. Prescribing information. AbbVie. April 2019. Available at: https://www.rxabbvie.com/pdf/skyrizi_pi.pdf Accessed May 8, 2019.
- SKYRIZI- risankizumab-rzaa. U.S. National Library of Medicine. April 23, 2019. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7148c8eb-b39e-e20a-6494-a6df82392858&audience=professional Accessed May 8, 2019.